Latest / PETRI DISH PERSPECTIVES
September 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail
Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026!
This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless dealmaking streak with a $3.25 billion InnoCare partnership. On the regulatory front, the FDA approved…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.